Morgan Stanley Forma Therapeutics Holdings, Inc. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$7.12 - $20.24 $291,863 - $829,678	40,992 Added 5.77%	751,051 $15 Million
Q2 2022 Oct 27, 2022	BUY	$5.1 - $10.0 $993,576 - $1.95 Million	194,819 Added 37.81%	710,059 $4.89 Million
Q2 2022 Aug 15, 2022	BUY	$5.1 - $10.0 $993,576 - $1.95 Million	194,819 Added 37.81%	710,059 $4.89 Million
Q1 2022 Oct 27, 2022	SELL	$8.34 - $14.69 $1.62 Million - $2.86 Million	-194,819 Reduced 27.44%	515,240 $4.79 Million
Q1 2022 May 13, 2022	BUY	$8.34 - $14.69 $2.88 Million - $5.06 Million	344,746 Added 202.2%	515,240 $4.79 Million
Q4 2021 Feb 14, 2022	SELL	$13.6 - $24.89 $161,214 - $295,046	-11,854 Reduced 6.5%	170,494 $2.43 Million
Q3 2021 Nov 15, 2021	BUY	$21.22 - $25.7 $3.87 Million - $4.69 Million	182,348 New	182,348 $4.23 Million

26.5K

Ticker FMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,860,400
Market Cap $958M
Description
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobin...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.